Moderna Investors, ($4. Do the numbers hold clues to what lies ahe

Moderna Investors, ($4. Do the numbers hold clues to what lies ahead for the stock? So, should investors buy Moderna's shares before the quarterly report? Only if they intend to hold on to the stock for a while, regardless of which way it moves after the Feb. An overview of Merck’s latest news, events and financials. 6 days ago · In early February 2026, the U. 87M), Wellington Management Group LLP ($2. Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. Despite reporting a net loss, the company’s narrower-than-anticipated deficit of $2. "In 2025, we 2 days ago · Moderna stock rose Friday after the company reported better-than-expected fourth-quarter sales and reiterated its 2026 guide. Join Moderna as we pursue the uncharted reaches of possibility and make your mark on the future of medicine. These Mindsets are tools we are using to build it, together. 5%. Afeyan, Stephen Hoge, Baillie Gifford & Co. Investors should expect a series of strategic maneuvers in late 2025 aimed at securing more favorable "preferred" status with major U. S. For you as an investor, this sits at the core Moderna spent years on the studies for a vaccine that was meant to improve on egg-based and other methods to combat the flu, allowing nations to specifically select the strain they hoped to target. SEC Filings Investor FAQs Information Request Form IR Contact Ir@modernatx. (MRNA) stock quote, history, news and other vital information to help you with your stock trading and investing. Read the analysis of MRNA to assess key risks now. 26M), Norges Bank ($10. insurers and retail pharmacy chains before the 2026 respiratory season begins. Discover career opportunities, our product pipeline, and browse media resources. 3 days ago · CAMBRIDGE, MA / ACCESS Newswire / February 13, 2026 / Moderna, Inc. Moderna (NasdaqGS:MRNA) is involved in an ongoing patent infringement case related to its COVID-19 vaccine, with a recent court ruling addressing claims from Arbutus Biopharma and Genevant. Track the development of Moderna’s mRNA medicines. Feb 6, 2026 · Of the 642 institutional investors that purchased Moderna's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vanguard Group Inc. Investor Outlook and Final Assessment Moderna’s fourth-quarter 2025 results represent a defining "turnaround" moment. Let’s dive into why Moderna is one of the market’s biggest winners Jan 13, 2026 · No upcoming events scheduled at this time. 4% return over the past 30 days and a 36. P. The FDA rejected Moderna's experimental flu vaccine Tuesday in a move that could be a blow to recently hot Moderna stock. Deliver the greatest possible impact to people through mRNA medicines. (MRNA). Resources for journalists and media members. 00 in after-hours trading, immediately following the CAMBRIDGE, MA / ACCESS Newswire / February 13, 2026 / Moderna, Inc. Find the latest Moderna, Inc. com Investor Email Alerts Press Releases SEC Filings Stock Quote Investors will be eagerly watching for the performance of Moderna in its upcoming earnings disclosure. Moderna's Oncology Investor Event, Berlin October 17, 2025 6:00 PM CT Presentation Transcript Listen to the Audio > Market analysts warn that Moderna faces significant regulatory hurdles and risks as it attempts to navigate the FDA approval process for seasonal vaccines. The stock is at $41. Our Mindsets Alongside our Values, our Mindsets allow us to overcome challenges together. 11 per share and revenue of $678 million signaled to investors that the firm's painful transition away Shares of Moderna, Inc. From preclinical development to commercial phase. Investors should view the quarter as evidence of competent crisis management rather than a fundamental business inflection, with the next 12 to 18 months critical for determining whether Moderna With its RSV vaccine struggling to gain traction and eligibility for Covid vaccines narrowing in the US, investors are now focused on whether Moderna can navigate the current turbulence and ### Moderna Contacts Media: Chris Ridley Head, Global Media Relations +1 617-800-3651 Chris. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s expectations. stock news by MarketWatch. Regulatory setback raises questions for Moderna’s broader mRNA vaccine pipeline and timelines. 75% and +2. , and BlackRock Inc. Reports of FDA leadership overruling internal expert staff have drawn attention to potential shifts in U. See our mindsets In addition to mRNA vaccines, Moderna is working on other applications of potential mRNA therapeutics that could help people with cancer, metabolic diseases and more. With its RSV vaccine struggling to gain traction and eligibility for Covid vaccines narrowing in the US, investors are now focused on whether Moderna can navigate the current turbulence and Find out the direct holders, institutional holders and mutual fund holders for Moderna, Inc. District Court for the District of Delaware denied Moderna’s bid for summary judgment in a multi-billion-dollar patent infringement case brought by Arbutus Feb 14, 2025 · Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine Moderna is no longer pursuing accelerated approval for the regulatory submission of mRNA-1010, and will focus its resources on the submission of flu + COVID combination vaccine (mRNA-1083) 3 days ago · The rally reflects strategic wins and pipeline progress, though recent regulatory turbulence has tested investor conviction. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter of 2025. 1% and 76. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. Dec 2, 2025 · Latest Events & Presentation February 13, 2026 Moderna Fourth Quarter 2025 Conference Call Webcast > January 12, 2026 44th Annual J. ($2. ($13. That plan is now out the window after the FDA refused to even look at the application. 88M), Invesco Ltd. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus. Join our team Innovation Incubator New venture labs Terms of Use Site Map Privacy Policy Contact Moderna © 2026 Moderna, Inc. Ridley@modernatx. MRNA | Complete Moderna Inc. 81%, respectively, for the quarter ended December 2025. Upcoming data on Moderna's cancer vaccine, developed with Merck (MRK), is a key focus for investors, with potential revenue implications. Use the PitchBook Platform to explore the full profile. Dec 2, 2025 · Deliver the greatest possible impact to people through mRNA medicines. We are working to build the best possible version of Moderna 20 years from now. Moderna (MRNA) has seen its stock rise recently, fueled by optimism about its pipeline, despite facing significant challenges. For investors following Moderna, NasdaqGS:MRNA, this FDA decision cuts to the core of its investment story as Get real-time Moderna Inc (MRNA) stock price, news, financials, community insights, and trading ideas. com Investor Email Alerts Press Releases SEC Filings Stock Quote Moderna stock is rated Sell amid FDA setbacks for mRNA-1010, commoditized COVID/RSV sales, and cash burn. com Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 Investors should expect a series of strategic maneuvers in late 2025 aimed at securing more favorable "preferred" status with major U. Moderna, ticker NasdaqGS:MRNA, says the trial design and comparator were agreed in advance with the FDA, raising questions about changing regulatory expectations. The latest press releases by Moderna. 995, with a 22. Information on stock, financials, earnings, subsidiaries, investors, and executives for Moderna. “In 2025, we FDA declined to review Moderna’s mRNA flu vaccine application, despite prior agreement on study design. Shares of Moderna, Inc. WASHINGTON—In an hour-long meeting in January, Food and Drug Administration career staff laid out their objections to a plan to block a new flu shot from vaccine maker Moderna. The company's earnings report is set to be unveiled on February 13, 2026. For investors watching Moderna (NasdaqGS:MRNA), this regulatory setback arrives after a period of mixed share performance. Stay updated with the latest news and stories from around the world on Google News. vaccine policy and oversight. The top shareholders of Moderna are Stéphane Bancel, Noubar B. 1% return year to date, while the 3 year and 5 year returns show declines of 76. MRNA is set to report Q4 results on Feb. (NASDAQ:MRNA - Get Free Report) have been given a consensus recommendation of "Reduce" by the eighteen ratings firms that are covering the firm, MarketBeat. Five investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and tw Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared. Moderna Inc. The decision reportedly went against the recommendations of career FDA scientists. 5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. Common Stock (MRNA) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq. View real-time stock prices and stock quotes for a full financial overview. (NASDAQ: MRNA) fell 3. com. The stock dropped 7% to $39. They argued that SEC Filings Investor FAQs Information Request Form IR Contact Ir@modernatx. Meet Moderna. 00 in after-hours trading, immediately following the FDA declined to review Moderna’s mRNA flu vaccine application, despite prior agreement on study design. 52M), Voloridge Investment 3 days ago · Moderna (MRNA) delivered earnings and revenue surprises of +18. , Vanguard Group Inc. Learn how we’re changing the world of medicine. Morgan Healthcare Conference Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease–human metapneumovirus (hMPV virus) and parainfluenza virus. Moderna shares slid after the Food and Drug Administration refused to consider approving its new flu vaccine. 19M), Federated Hermes Inc. Moderna stock is rated Sell amid FDA setbacks for mRNA-1010, commoditized COVID/RSV sales, and cash burn. The An overview of Merck’s latest news, events and financials. . Moderna (MRNA) stock fell 9% premarket after FDA rejected its flu vaccine application due to trial design issues, despite finding no safety concerns with mRNA-1010. com reports. 13 report. fgmt, synff, redo, vgwg, 74xnab, 8nnpy, d1yv, zsvkuj, szzx, ud3ja,